Viridian Therapeutics review

The short version

Viridian (formerly miRagen Therapeutics, renamed in 2020) wants to do to Amgen’s Tepezza what many biotech challengers try: offer the same benefit with less burden for patients. Thyroid eye disease makes the eyes bulge and can cause double vision. Tepezza proved that a large market exists for it, and Viridian’s Lumvoa is now the first serious rival. A home injection, elegrobart, is next in line.

The latest FDA decision: approved

On 26 June 2026, four days early, the FDA approved Lumvoa (veligrotug) for thyroid eye disease, for both active and long-lasting disease, Viridian’s first approved drug (HCPLive). The shares rose about 8% around the news, as our FDA Decision Calendar shows.

What it makes

Lumvoa is given as five infusions every three weeks. In the Phase 3 THRIVE trial, in active disease, 70% of patients had a meaningful reduction in eye bulging vs 5% on placebo. In THRIVE-2, in long-lasting disease, it was 56% vs 8% (Viridian’s THRIVE-2 results). Reported side effects include infusion reactions (about 9%), high blood sugar (12%) and hearing problems, which may be permanent, so hearing should be checked during treatment.

Elegrobart is built on the same idea but injected at home with a small autoinjector. Both of its Phase 3 trials (REVEAL-1 and REVEAL-2) were positive at week 24, and the filing is planned for Q1 2027. Viridian is also developing FcRn blockers for autoimmune diseases.

Is it really new?

Lumvoa is an improved version of an existing idea, not a new one: it hits the same target as Tepezza. What is new is the convenience, and a label that covers patients regardless of how active or how old their disease is, based on trials in both groups. Elegrobart, if approved, would be a bigger change, because patients would no longer need to visit an infusion centre.

The competition

Amgen’s Tepezza lists at about $525,000 a course, according to Viridian’s annual report (10-K). Analysts have said Lumvoa’s benefit looks “in the ballpark” of Tepezza’s, with five infusions vs eight and shorter sessions. No trial has compared them directly. Amgen has size and long relationships with doctors. Others, including Sling’s linsitinib pill, are testing different approaches.

Money

Viridian held $981.5 million in cash on 30 June 2026, after raising about $394 million in May. It lost $127.1 million in Q2, as selling costs rose to $55 million ahead of the launch (Q2 2026 results). By 31 July, its sales team had reached 95% of about 2,000 core prescribing doctors. We could not find a published price for Lumvoa.

Risks

• Launch risk. Doctors are used to Tepezza, and insurers must agree to pay.
• Safety. Hearing loss is a known concern of this drug type, and a problem would affect the whole class.
• Amgen’s response. A large rival can defend its market with price or contracts.
• Newer pills. An oral option could undercut infusions and injections in time.

Our take

Viridian has a clear plan: take share with Lumvoa, then widen the market with a home injection. The science is mostly proven, so the story is now about execution. The first sales figures will show how quickly doctors switch. If the launch goes well, the company’s market value of around $2.8 billion leaves room to grow.